Trends in interventional clinical trials: Biologics

INTERVENTIONAL STUDIES: BIOLOGICSResults | Phases | Purpose | Endpoints | Funding | DesignSource: ClinicalTrials.govData download date: December 26, 2016Publication date: January 29, 2017 Analytical tool: IBM Watson

ARETE-ZOE, LLC: 1334 E Chandler Blvd 5A-19, 85048 Phoenix, AZ, USA | T:+1-480-409-0778 (24/7) | website: http://www.aretezoe.com/

DRUG STUDIESSTUDY RESULTSAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study ResultsNumber of Studies by Results over Time (completion date)

Drugs Biologics


Study ResultsBreakdown of Study Results by Phase

Drugs

Biologics

DRUG STUDIESSTUDY PHASESAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study PhasesNumber of Studies by Phase over Time (completion date)

Drugs Biologics

DRUG STUDIESSTUDY ENDPOINTSAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study EndpointsNumber of Studies by Endpoint over Time (completion date)

Drugs Biologics


Study EndpointsBreakdown of Study Endpoints by Phase

Drugs

Biologics

Drugs

DRUG STUDIESSTUDY FUNDINGAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study FundingNumber of studies by Funding over Time (completion date)

BiologicsDrugs


Study FundingBreakdown of Study Funding by Phase

Biologics

Drugs

DRUG STUDIESSTUDY PURPOSEAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study PurposeNumber of Studies by Purpose over Time (completion date)

BiologicsDrugs


Study PurposeBreakdown of Study Purpose by Phase

Biologics

Drugs

DRUG STUDIESSTUDY DESIGN: ALLOCATIONAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study Design: AllocationNumber of Studies by Allocation over Time (completion date)

BiologicsDrugs


Study Design: AllocationBreakdown of Study Design by Phase

Biologics

Drugs

DRUG STUDIESSTUDY DESIGN: ASSIGNMENTAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study Design: AssignmentNumber of studies by Assignment over Time (completion date)

BiologicsDrugs

DRUG STUDIESSTUDY DESIGN: MASKINGAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study Design: Masking Number of studies by Masking over Time (completion date)

BiologicsDrugs

DRUG STUDIESSTUDY RECRUITMENTAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study RecruitmentNumber of Studies by Recruitment over Time (completion date)

BiologicsDrugs


Study RecruitmentBreakdown of Study Recruitment by Phase

Biologics

Drugs

DRUG STUDIESSTUDY DEMOGRAPHICSAll studies with completion date in the future marked as 2018Studies with start date in 2017 and beyond removed



Study Demographics: Gender Number of studies by Gender of participants over Time (completion date)

BiologicsDrugs


Study Demographics: GenderBreakdown of Study Participation by Gender by Phase

Biologics

Drugs

ARETE-ZOE, as a consultancy, provides solutions to complex problems in the high stakes and high consequence environment of Global Pharmaceuticals, including clinical research, healthcare informatics, and public health. We blend established, Pharma sector methodologies, innovation, and adaptations/transfers from other sectors to identify and resolve consequential practices that pose risk and often result in avoidable patient casualty. However, we are specifically, not a patient advocacy group but believe in optimizing organizational effectiveness and that smart business is agile, competitive and profitable, while intrinsically safe, secure, and resilient. We work within a global context because transnational interests influence national circumstances and choices at point of prescription.

ARETE-ZOE, provides full spectrum organizational and operational risk management consultancy. Our published materials provide a glimpse of some aspects of our services to demonstrate both knowledge and ongoing participation within the Pharmaceutical Industry. Our analysis and consultancy includes all channels of misuse, diversion, counterfeiting and illicit exploitation of pharmaceuticals, medical devices, and precursor chemicals. Our advisement is to manufactures, jurisdictional entities, insurers, legislators, litigators, patients, and health care providers. This scope also frequently segues into the nexus of crime and terrorism as significant influencers that undermine sector integrity differentiated from other criminal activity. Obviously, vulnerability assessment, information collection management and intelligence production supporting decision-making for risk reduction and interventions are routinely within the scope of our services as well as design and implementation of operational control measures.


Trends in interventional clinical trials: Biologics

Healthcare